Less than half of American [4] and even fewer Chinese [5,6] patients with AIS are treated with recombinant tissue plasminogen activator within the time frame recommended by the American Heart Association and American Stroke Association [door-to-needle (DTN) time ≤ 60 min] [7], which has been validated by the Get With The Guidelines—Stroke program [8]. This evidence concerns the gene PLAT and Stroke.